trivalent influenza split vaccine

**Trivalent influenza split vaccine** is an inactivated, split-virion vaccine that provides active immunization against influenza by inducing antibodies to the hemagglutinin antigens of three influenza virus strains. Each annual formulation contains two influenza A subtypes (typically H1N1 and H3N2) and one influenza B lineage virus (currently B/Victoria)[1][3][5][7]. The "split" process involves disruption of viral particles, usually with detergents like sodium deoxycholate, to reduce reactogenicity while retaining immunogenic components (mainly hemagglutinin and neuraminidase)[5][7]. The 2024–2025 US formulation includes: - A/Victoria/4897/2022 (H1N1)pdm09-like virus - A/Thailand/8/2022 (H3N2)-like virus - B/Austria/1359417/2021 (B/Victoria lineage)-like virus Vaccines are typically administered intramuscularly, and use may include single or multi-dose vials, some with preservative (thimerosal) in multi-dose format[5][7]. The vaccine is indicated for annual prevention of influenza in adults and children 6 months and older[7]. The mechanism of action is immunization against circulating strains by generating adaptive (humoral) immune responses to viral proteins (mainly hemagglutinin).

Brand names

FLULAVALAfluriaFluzone

Other names

trivalent influenza vaccinetrivalent seasonal influenza vaccineTIVtrivalent inactivated influenza vaccinetrivalent split-virion vaccineinfluenza virus vaccine (trivalent, split)